Compare OVID & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | ASMB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | OVID | ASMB |
|---|---|---|
| Price | $2.56 | $19.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $6.40 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 2.4M | 201.9K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.90 | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $1.18 | $19.20 |
| 52 Week High | $3.11 | $39.71 |
| Indicator | OVID | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 42.68 |
| Support Level | $2.12 | $19.25 |
| Resistance Level | $2.67 | $21.65 |
| Average True Range (ATR) | 0.24 | 1.16 |
| MACD | 0.03 | 0.37 |
| Stochastic Oscillator | 44.95 | 26.65 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.